Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.34 0.1299 +61.86%
AGIO $43.66 3.3100 +8.20%
PVCT $0.98 0.0701 +7.70%
GALT $5.22 0.3600 +7.41%
SPPI $7.91 0.4000 +5.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $17.00 -1.7700 -9.43%
IMNP $3.74 -0.2099 -5.31%
CRIS $1.59 -0.0650 -3.94%
CERU $4.49 -0.1800 -3.85%
GALE $2.15 -0.0500 -2.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Concordia Healthcare Corp. Initiates Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy with PHOTOFRIN®

(MarketWatch) Aug 5, 2014 - Concordia Healthcare Corp. today announced the initiation of a randomized Phase 3 clinical trial to treat a rare form of bile duct cancer for which there currently is no acceptable therapy.
read article 

Many Blacks Are Unaware of a Skin Cancer that Primarily Affects Dark-skinned People

(Washington Post) Aug 4, 2014 - Many people of color assume that they don’t have to worry about melanoma. They’re wrong.
read article (free registration required) 

Digital Tomosynthesis May Aid in Lung Cancer Screening

(RSNA) Aug 1, 2014 - Digital tomosynthesis shows promise as lower-dose, lower-cost lung cancer screening option.
read article 

Singapore First to Develop Molecular Test Kit for Kidney Cancer

(Yahoo! Finance/Singapore Business Review) Aug 1, 2014 - Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH), and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict how kidney cancer patients will turnout after treatment.
read article 

Single-fraction Radiation Therapy as Effective as Multiple-fraction Radiation Therapy for Palliation of Bone Metastases

(ASTRO) Aug 4, 2014 - Standardizing prescribing practices for single-fraction radiation therapy (SFRT) for palliation of bone metastases could lead to cost savings and improvement in patients’ quality of life, according to a new study.
read press release 

Nanotax Phase I Clinical Trial Shows Promise for Treating Abdominal Cancers

(University of Kansas Cancer Center) July 23, 2014 - A repurposed drug commonly used to treat ovarian cancer saw positive results and minimal side effects in early clinical trials.
read article 

Y-90 Shows Promise in Treating Metastatic Breast Cancer

(RSNA) Aug 1, 2014 - Research shows that Y90 radioembolization is promising in treating breast cancer that has spread to the liver.
read article 

Swedish Study: Mammograms Beneficial in Women 75 and Up

(The Seattle Times) Aug 4, 2014 - Mammograms detect breast cancer at an earlier stage in women 75 and older, allowing less aggressive treatment, researchers found. But others worry that detection of low-stage cancers unlikely to progress will lead to overtreatment.
read article 

FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted

(MarketWatch) Aug 5, 2014 - Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
read article 

Positive Interim Results Reported for Arzerra as Maintenance Therapy for Relapsed CLL

(Healio) Aug 5, 2014 - Results from an Independent Data Monitoring Committee interim analysis have found that ofatumumab met the primary endpoint of improving PFS among patients with relapsed chronic lymphocytic leukemia, manufacturers GlaxoSmithKline and Genmab reported.
read article 

Roche's MabThera SC to be Funded on NHS

(PharmaTimes [UK]) Aug 5, 2014 - NHS England has approved funding for a new sub-cutaneous formulation of Roche’s cancer drug MabThera (rituximab) which offers patients with follicular lymphoma a more convenient treatment option while potentially saving the National Health Service a lot of cash.
read article 

FDA Expands Approval of Drug to Treat Pompe Disease to Patients of All Ages; Removes Risk Mitigation Strategy Requirements

( Aug 1, 2014 - The U.S. Food and Drug Administration today announced the approval of Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than 8 years of age.
read press release 

FDA Approves Jardiance to Treat Type 2 Diabetes

( Aug 1, 2014 - The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes.
read press release 

PTC Therapeutics' Muscle Disorder Drug Wins Conditional EU Approval

(Reuters) Aug 4, 2014 - PTC Therapeutics Inc said European regulators have given conditional approval to its muscle wasting disorder drug, sending its shares up 4.5 percent in early trading on Monday.
read article 

Secret Serum Likely Saved Ebola Patients

(CNN) Aug 4, 2014 - Three top secret, experimental vials stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.
read article 

New FDA Process Speeds Approval of High-priced Breakthrough Drugs

(San Francisco Chronicle) Aug 3, 2014 - Gilead Sciences' hepatitis C drug is racking up record-setting sales. Vertex Pharmaceuticals' drug is the first to treat an underlying cause of cystic fibrosis. The newest drug from Pharmacyclics treats rare blood cancers. All these medicines have something in common besides their high prices.
read article 

Drs. Imad El-Jassous and Pablo Reyes, Jr. Join Florida Cancer Specialists & Research Institute

(FCS) Aug 4, 2014 - Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in Florida, is pleased to announce that Dr. Imad El-Jassous and Dr. Pablo Reyes, Jr., formerly of Lake Cancer Center, have joined the statewide practice.
read corporate press release 

Colorado State University Helps Lead International Charge on New Radiation Treatment for Cancer

(Colorado State University) July 31, 2014 - Imagine a targeted radiation therapy for cancer that could pinpoint and blast away tumors more effectively than traditional methods, with fewer side effects and less damage to surrounding tissues and organs.
read press release 

The $16.7 Million X-ray: Possible Beats Probable in Court

( blog) Aug 3, 2014 - In a recent verdict a jury in Massachusetts awarded $16.7 million in damages to the daughter of a Bostonian lady who died from lung cancer at 47, for a missed cancer on a chest x-ray.
read article 

Optim Oncology and Urology Centers of Oklahoma Join The US Oncology Network to Bring World-Class Treatments and Cutting-Edge Research to Oklahomans

(The US Oncology Network) Aug 4, 2014 - Optim Oncology and Urology Centers of Oklahoma, divisions of Oklahoma Multispecialty Group and leaders in providing quality oncology and urology care throughout Oklahoma, announced today they have joined The US Oncology Network.
read corporate press release 

NCI Community Oncology Research Program (NCORP) Gets Underway

(NCI News Note) Aug 1, 2014 - The National Cancer Institute (NCI) has awarded 53 new 5-year grants to researchers across the country to conduct multi-site cancer clinical trials and cancer care delivery research studies in their communities.
read article 

ASCO Concerned About Proposed Changes to USP Requirements on Handling Hazardous Drugs

(ASCO in Action) Aug 1, 2014 - On July 31, 2014, ASCO submitted comments on the United States Pharmacopeial Convention’s (USP) proposed General Chapter 800, “Hazardous Drugs – Handling in Healthcare Settings,” which will impose overly burdensome new requirements on oncology practices in handling toxic materials without clear evidence of positive impact to patients and practice staff.
read article 

Cancer Genetics, Inc. Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL)

(Cancer Genetics) Aug 4, 2014 - Cancer Genetics, Inc. announced today the launch of an updated MatBA®-CLL/SLL test which provides greater clarity of risk and outcome for patients.
read corporate press release 

Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies

(Yahoo! Finance) Aug 4, 2014 - Heat Biologics, Inc. announced today that it has amended the Phase 1/2 clinical protocol for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer after transurethral resection of bladder tumor (TURBT).
read article 

XBiotech Begins Patient Enrollment in Phase III Trial of Xilonix to Treat Colorectal Cancer

(Pharmaceutical Business Review) Aug 4, 2014 - US-based biopharmaceutical firm XBiotech has initiated patient enrollment in its European Phase III trial using its new cancer drug Xilonix to treat colorectal cancer.
read article